Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient ...
Now, researchers in a lab at the University of Minnesota, using a drug called CD200AR-L, have developed their own vaccine to ...
The molecule is also being tested in over 100 vaccine clinical trials. Rising QS-21 demand from the pharmaceutical industry ...
Scientists at Sanaria and Seattle Children's Research Institute's Center for Global Infectious Disease Research (CGIDR) have unveiled a groundbreaking malaria vaccine, Sanaria® PfSPZ-LARC2 Vaccine, ...
The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.
Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.
Bengaluru: Bharat Biotech group company Biovet, an innovative animal health vaccine producer based in Mallur, Karnataka, has ...
Bharat Biotech's group company, Biovet, has launched the world's first-ever Lumpy Skin Disease (LSD) vaccine, Biolumpivaxin, ...
Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025 ( Sanofi ...
Experts are concerned about the Clade 1 mpox virus that has been spreading quickly in west and central Africa since 2023.
VAX-31’s safety, tolerability, and immunogenicity are being assessed in this trial on healthy infants. Vaxcyte anticipat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results